This is the first randomized controlled trial investigating the efficacy and safety of low-dose prolonged methylprednisolone administration in early ARDS. This study tested a pathophysiologic ...

Meta-analysis of subjects from 4 randomized clinical trials supports the potential of enobosarm to optimize weight loss Start ...

Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus ...

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) shares are gaining after announcing positive European Medicines Agency feedback on its proposed single confirmatory Phase 3 study of investigational ...

A spinoff company has been formed to produce a hormone supplement that reduces lung damage, but researchers still need to ...

What is the moon phase today? Today, Oct. 21, 2024, the moon is 19 days old and is in the Waning Gibbous phase of its lunar cycle. It is 78% illuminated. Moon phases reveal the passage of time in ...

This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is ...

AFTER a perfect record in this year’s championship, Ballygalget will be hoping that they can cap their season off in style ...

To schedule a meeting with Edesa during the conferences, please contact conference organizers or the company directly at [email protected].

Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R.

IPO前，泽辉生物董事长、CEO泽辉生物的母亲金韵女士通过XiangjingPhase II持股38.33%，通过Zephyrm Tongchuang Phase II持股6.65%，为公司大股东。Zephyrm Tongchuang Holding持股为11.04%，Huijing Yonglong持股为4.56%。